GlassScriptPhysician profile
Mohammad Alasaad
NPI 1801186663
$5,778.63
in general payments reported to CMS, 2019-2025
31 companies · $903 in 2025
The $903 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,526 · 2020: $2,457 · 2021: $112 · 2022: $15.24 · 2023: $292 · 2024: $472 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,578 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,578.23 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,841.23 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Ensite Precision, Merlin@Home |
| Medtronic Vascular, INC. | $1,522.15 | 2019-2020 | |
| Abiomed | $287.19 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $250.89 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $238.01 | 2019-2025 | Farxiga, Lokelma |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $214.57 | 2019-2025 | Lifevest |
| Pfizer INC. | $141.88 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $135.64 | 2019-2024 | Xarelto |
| Cardinal Health 200 LLC | $120.39 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $114.62 | 2023-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $100.17 | 2025 | Symplicity G3, Cobalt Dr Mri Surescan |
| Actelion Pharmaceuticals US, INC. | $89.00 | 2025 | Opsumit, Uptravi |
| Stryker Corporation | $62.34 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Chiesi USA, INC. | $60.89 | 2024-2025 | Kengreal, Cleviprex |
| Merck Sharp & Dohme LLC | $56.50 | 2023 | Verquvo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $56.32 | 2023-2024 | Acuity Steerable, Lux-Dx Insertable Cardiac Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.62 | 2024-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $52.06 | 2025 | Onpattro, Amvuttra |
| Philips North America LLC | $50.44 | 2023 | |
| Lantheus Medical Imaging, INC. | $46.82 | 2023 | Definity |
| Edwards Lifesciences Corporation | $40.40 | 2024 | Sapien 3 Ultra Resilia |
| Amgen INC. | $36.04 | 2024-2025 | Repatha, Repatha |
| Azurity Pharmaceuticals, INC. | $29.44 | 2024-2025 | Edarbyclor |
| Kestra Medical Technology Services, INC. | $29.26 | 2025 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $28.54 | 2025 | |
| Glaxosmithkline, LLC. | $25.32 | 2025 | Shingrix, Arexvy |
| Cook Medical LLC | $24.93 | 2025 | Cook Celect |
| Altathera Pharmaceuticals LLC | $22.16 | 2024 | Sotalol Hydrochloride |
| Lexicon Pharmaceuticals, INC. | $17.10 | 2023 | Inpefa |
| Inspire Medical Systems, INC. | $15.59 | 2025 | Inspire |
| Ekos Corporation | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Alasaad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.